The Online Investor

Beam Therapeutics Stock Forecast

Recent Beam Therapeutics Stock Price   Beam Therapeutics Stock Forecast Price
$66.09 Beam Therapeutics stock forecast: higher
+48.10%
$97.88
 As of 2022-08-12
Recent Beam Therapeutics Analyst Ratings Breakdown
  Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong buy ratings: 7 7 7 7
Buy ratings: 0 0 0 0
Hold ratings: 3 2 1 1
Sell ratings: 0 0 0 0
Strong sell ratings: 0 0 0 0
Average rating: 1.6 1.44 1.25 1.25
In the last row of the above table, the average rating presented is from 1 to 5 where 1 means Strong Buy and 5 means Strong Sell.

The presented Beam Therapeutics stock forecast (traded under symbol BEAM), for forward-twelve-months price target as shown at the top of this page, gives you the average Beam Therapeutics stock forecast for forward target price for symbol BEAM, across the 8 analysts covering Beam Therapeutics (BEAM), as reported in data provided by Zacks Investment Research via Quandl.com.

Investors should also take note that the median Beam Therapeutics stock forecast price target (i.e. representing the middle ground number where half of analysts had a higher Beam Therapeutics stock forecast and half had a lower Beam Therapeutics stock forecast) was $101.0 as of 2022-08-12 (which is a different mathematical metric versus taking the average or mean), while the highest Beam Therapeutics stock forecast in the analyst group was $130.0, and the lowest Beam Therapeutics stock forecast in the analyst group was $61.0, with a standard deviation of $24.689. Get the latest Zacks research report on BEAM — FREE

Slideshow Top Analyst Picks of the Dow
Slideshow The Top 20 Largest U.S. Stocks By Market Cap

Company Name: 
Beam Therapeutics Inc
Website: 
www.beamtx.com
Sector: 
Biotechnology
Number of ETFs Holding BEAM: 
35
Total Market Value Held by ETFs: 
$1.22B
Total Market Capitalization: 
$4.62B
% of Market Cap. Held by ETFs: 
26.44%
Quotes delayed 20 minutes

Email EnvelopeFree BEAM Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (3.40 out of 4)
44th percentile
(ranked lower than approx. 56% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Beam Therapeutics Stock Forecast (BEAM) Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.